NUDC

Across TCGA pan-cancer cohorts, NUDC RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated NUDC data layer compared with 1 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NUDC RNA is associated with worse overall survival. In most high-consensus cancer types, elevated NUDC expression acts as an unfavorable survival marker, although some lineages such as SCLC and STAD show a favorable association.

LIHC, LGG, and MESO are the cancer types where NUDC RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.559	0.771	<.001	73	view →
LGG	DFS	Median	All	0.648	0.833	<.001	42	view →
MESO	OS	Tertile	IV	0.257	0.768	.006	38	view →
LAML	DFS	Quartile	All	0.184	0.576	.001	32	view →
ACC	OS	Quartile	IV	0.327	0.915	.006	32	view →
SCLC	DFS	Quartile	II,III,IV	0.717	0.219	.003	25	view →
ESCA	OS	Median	III,IV	0.407	0.686	.003	24	view →
KIRP	DFS	Median	III,IV	0.547	0.848	.011	24	view →
SARC	DFS	Median	All	0.525	0.694	<.001	20	view →
STAD	DFS	Median	II,III,IV	0.682	0.543	.012	19	view →
UCS	DFS	Tertile	IV	0.361	0.938	.024	16	view →
READ	DFS	Median	II,III,IV	0.851	0.740	.014	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

NUDC–LIHC (OS)

Open the LIHC breakdown →